Sunday, 18 February 2018

Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
Thursday, the companies revealed Bavencio (avelumab) had failed to outdo chemo at extending the lives of second-line lung cancer patients with PD-L1-positive tumors. And the way Evercore ISI analyst Umer Raffat sees it, there’s no “good reason” to explain the flop.

No comments:

Post a Comment

Mental health could cost the global economy up to $16 trillion between 2010 and 2030

According to an expert, mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 tr...